Nurix Therapeutics Inc (NRIX) Return on Equity ROE from the third quarter 2026 to third quarter 2025 and annually, average high and low, overall ranking from Aug 31 2026 to Aug 31 2025 - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Nurix Therapeutics Inc   (NASDAQ: NRIX)

Nurix Therapeutics Inc 's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics


What is ROE for Nurix Therapeutics Inc in the third quarter 2026?
Nurix Therapeutics Inc achieved a return on average equity (ROE) of 49.34 % in its third quarter 2026 a new company high.

ROE has advanced compared to -76.09% in the second quarter 2026, due to net income growth.

Within the Major Pharmaceutical Preparations industry 16 other companies had a higher return on equity. While return on equity, the total ranking has deteriorated compared to the second quarter 2026 from 3218 to 3363.

What is ROE?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Equity (Aug 31 2026)
III. Quarter		 (May 31 2026)
II. Quarter		 (Feb 28 2026)
I. Quarter		 (Nov 30 2025)
IV. Quarter		 (Aug 31 2025)
III. Quarter
Y / Y Equity Change 160.12 % -10.05 % -0 % 2.23 % -
Y / Y Net Income Change - - - - -
Net Income (TTM) in Millions 295 -341 -295 -264 -245
Return On Equity (TTM) 49.34 % -76.09 % -64.21 % -57.51 % -53.57 %
NRIX's Total Ranking # 3363 # 3218 # 63 # 138 # 2934
Equity (TTM) in Millions 968 403 481 539 372
Seq. Equity Change 140.5 % -16.28 % -10.74 % 44.73 % -16.83 %
Seq. Net Income Change - - - - -

Back to NRIX Management Effectiveness >> NRIX's 5 Years Annual ROE >> Compare NRIX ROE to its Competitors
Return On Equity Company Ranking
Within: No.
Industry # 17
Sector # 37
Overall # 3363

Return On Equity Statistics
High Average Low
49.34 %
-47.4 %
-76.09 %
(Aug 31 2026)   (May 31 2026)





NRIX Annual Return On Equity (Nov 30 2025)
2025		 (Nov 30 2024)
2024		 (Nov 30 2023)
2023		 (Nov 30 2022)
2022		 (Nov 30 2021)
2021
Total Equity in Millions 539 527 200 304 342
Y / Y Equity Change 2.23 % 162.85 % -33.98 % -11.28 % 17.93 %
Net Income in Millions -264 -194 -144 -180 -117
Y / Y Net Income Change - - - - -
Return On Equity -49.09 % -36.73 % -71.8 % -59.39 % -34.24 %

Back to NRIX Management Effectiveness >> NRIX's 5 Years Annual ROE >> Compare NRIX ROE to its Competitors




More Return On Equity Ratios
Major Pharmaceutical Preparations Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
NRIX's' Return on Equity at Yahoo Finance
NRIX's Roe Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for NRIX's Competitors
Subscribers only: Roe for Nurix Therapeutics Inc 's Suppliers
Subscribers only: Return On Equity for NRIX's Customers




Companies with similar Return On Equity at Aug 31 2026, within Healthcare Sector ROE
3m Company  93.07 %
Nurix Therapeutics Inc   49.34 %
Medinotec Inc   10.97 %

Date modified: 2026-10-14T16:57:13+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.